Canaan Stock Drops After Q1 Loss Widens — Why CAN Is Under Pressure Now
Canaan shares fell 5.3% to $0.4127 in late-morning Nasdaq trading Thursday after the company reported a
Quantum Shares Tick Up in Pre-Market Trade After AI Storage Angle Draws Notice
Quantum Corp shares climbed 5.88% to $8.64 in pre-market trading Thursday after closing 5.84% higher Wednesday. No new company news accompanied the move. Quantum last reported fiscal Q3 revenue of $74.6 million
Sunrun Stock Jumps as Solar Names Rally; Cash Flow in the Spotlight
Sunrun Inc. shares closed at $13.69 Wednesday, up 3.9% on heavy volume, as solar stocks rallied broadly. First-quarter revenue rose 43% to $722.2 million, but the company reported negative Cash Generation of $59 million. Sunrun’s storage attachment rate hit a record 73%. The company warned that higher interest rates and policy changes could impact financing and costs.
Esperion Shares Flat at $3.16 as Archimed Bid Nears Endgame
Esperion Therapeutics shares held at $3.13 late Wednesday, just below Archimed’s $3.16-a-share cash offer, as investors assessed closing and milestone risks in the $1.1 billion take-private deal. The stock saw volume above 7 million shares. The merger includes a contingent value right tied to future drug sales. Esperion’s first-quarter revenue rose to $80.1 million, with a net loss narrowing to $25.2 million.
ARGX Stock Watch: Argenx Up Ahead of Immunovant Trial Data
argenx SE shares rose 0.7% to $803.67 Wednesday, trailing biotech peers after Immunovant reported positive rheumatoid arthritis trial data for IMVT-1402, sending its stock up 35.1%. VYVGART sales reached $1.3 billion last quarter. The FDA recently expanded VYVGART’s approval for generalized myasthenia gravis. argenx’s next key data releases are expected later this year.
Aurora Shares Bounce, but Traders Eye SEC Filing
Aurora shares rose 2.7% to $7.13 in midday trading Wednesday after Greylock-linked holders tied to director Reid Hoffman sold about 5.85 million shares last week at prices averaging $7.81 and $7.51. The stock rebounded after a two-day slide, with volume near 9.6 million shares and a market value around $13.9 billion. Aurora posted Q1 revenue of $1 million and a net loss of $223 million.
Icahn Enterprises Stock Holds Steady as Investors Eye Dividend Decision
Icahn Enterprises units rose 0.3% to $7.53 in midday Nasdaq trading Wednesday, days after the May 18 record date for its $0.50 quarterly distribution due in late June. Investors focused on IEP’s net asset value, which rose to $3.4 billion at March 31, helped by gains in CVR Energy but offset by $320 million in refining hedge losses. No new earnings were released in the past 24 hours.
Applied Optoelectronics rises premarket as insider sale filings arrive
Applied Optoelectronics shares rose 3.54% to $177.40 in premarket trading Wednesday after six senior officers filed Form 144 notices for proposed sales totaling about 201,489 shares, or $34.8 million. The filings followed a May 14 agreement allowing the company to sell up to $600 million in stock through Raymond James and Needham. The stock closed Tuesday at $171.33, down 1.1%.
Tabcorp Shares Bounce, But One High-Stakes Tote Deal Could Decide What Comes Next
Tabcorp shares closed at A$0.685 Tuesday, up 1.5%, but remain down about 40% since AUSTRAC launched an enforcement probe on May 7. CEO Gillon McLachlan is in talks with Racing NSW for a national tote deal, with further approvals pending. The AUSTRAC investigation triggered a sharp sell-off, erasing over A$700 million in market value.
Wesfarmers jumps as buyers return to ASX retail stocks
Wesfarmers shares closed up 2.4% at A$72.98 Tuesday, outperforming the S&P/ASX 200’s 1.17% gain to 8,604.7. Investors rotated back into consumer stocks after recent losses, with Wesfarmers trading 1.56 million shares. Woolworths rose 3.7% after a JPMorgan upgrade, while Coles gained 2.7%. Cost pressures persist, with CEO Rob Scott warning of potential price increases due to fuel and freight.
Applied Optoelectronics rises premarket as insider sale filings arrive
Applied Optoelectronics shares rose 3.54% to $177.40 in premarket trading Wednesday after six senior officers filed Form 144 notices for proposed sales totaling about 201,489 shares, or $34.8 million. The filings followed a May 14 agreement allowing the company to sell up to $600 million in stock through Raymond James and Needham. The stock closed Tuesday at $171.33, down 1.1%.
Tabcorp Shares Bounce, But One High-Stakes Tote Deal Could Decide What Comes Next
Tabcorp shares closed at A$0.685 Tuesday, up 1.5%, but remain down about 40% since AUSTRAC launched an enforcement probe on May 7. CEO Gillon McLachlan is in talks with Racing NSW for a national tote deal, with further approvals pending. The AUSTRAC investigation triggered a sharp sell-off, erasing over A$700 million in market value.
Wesfarmers jumps as buyers return to ASX retail stocks
Wesfarmers shares closed up 2.4% at A$72.98 Tuesday, outperforming the S&P/ASX 200’s 1.17% gain to 8,604.7. Investors rotated back into consumer stocks after recent losses, with Wesfarmers trading 1.56 million shares. Woolworths rose 3.7% after a JPMorgan upgrade, while Coles gained 2.7%. Cost pressures persist, with CEO Rob Scott warning of potential price increases due to fuel and freight.
CSL Rises, $5 Billion Cloud Remains
CSL Ltd shares closed up 2.57% at A$98.69 on Tuesday, recovering some ground after last week’s earnings reset, but remained 17.7% below their May 8 close. The company faces about $5 billion in additional non-cash impairments over FY26–27, following guidance cuts and asset write-downs. No new trading updates were issued Tuesday. Broader healthcare stocks also rose as the S&P/ASX 200 gained 1.17%.
Woodside Energy Stock Rises, But One Gas Fight Could Move It Next
Woodside Energy Group shares closed up 0.40% at A$32.28 in Sydney, trailing the S&P/ASX 200’s 1.17% gain, as investors weighed strong oil prices against new government plans to reserve 20% of east coast gas for domestic use from 2027. Company executives warned the policy could threaten future supply. Brent crude traded at $110.82 a barrel amid Middle East tensions.
Tate & Lyle Drifts Under Ingredion Offer as Deal Timeline Becomes Focus
Tate & Lyle shares traded at 514.5 GBX in London at 15:00 BST, down 1.25%, as investors awaited clarity on Ingredion’s possible takeover offer of up to 615p per share. The companies remain in talks, with a June 11 deadline for a firm bid. Tate & Lyle’s full-year results are due May 21. The stock price remains well below Ingredion’s proposed value.
CSP Inc. moves on ex-dividend day, small Nasdaq cybersecurity stock active
CSPI shares traded at $9.51, up 9 cents in thin volume, as the stock went ex-dividend for a $0.03 payout due June 15. The move followed a return to quarterly profit and 22% revenue growth reported May 7. Investors are watching if recent AZT PROTECT deployments lead to steadier revenue. Gross margin fell to 27.9% from 32% a year earlier.
Cipher Digital Stock Is Jumping Again — The AI Power Bet Behind CIFR’s Rally
Cipher Digital Inc. shares jumped 6.4% to $20.73 Thursday morning, outpacing a weaker tech market as the company pivots from bitcoin mining to AI data-center infrastructure. Trading volume reached 8.5 million shares, with a market value near $8.4 billion. Morgan Stanley raised its price target to $42.50 this week. Cipher reported $35 million in Q1 revenue and negative adjusted EBITDA of $48 million.
Canaan Stock Drops After Q1 Loss Widens — Why CAN Is Under Pressure Now
Canaan shares fell 5.3% to $0.4127 in late-morning Nasdaq trading Thursday after the company reported a first-quarter net loss of $88.7 million and forecast weaker Q2 revenue of $35 million to $45 million. First-quarter revenue dropped to $62.7 million from $196.3 million in the prior quarter. Trading volume reached 3.8 million shares. Several bitcoin-mining peers rose.
POM Stock Nears 12 Cents as Nasdaq Deadline for Pomdoctor Gets Focus
Pomdoctor Limited’s Nasdaq-listed ADSs fell to $0.1153 in early U.S. trading Thursday, down $0.0094 from the previous close, with 172,520 shares traded. The company remains below Nasdaq’s $1 minimum-bid requirement and has until July 28 to regain compliance. Pomdoctor recently reported a wider 2025 net loss despite higher revenue.
NCS Multistage Shares Tick Up on Tuesday
NCS Multistage traded at $44.10 in early Nasdaq action Thursday, up about 1% on thin volume of 2,120 shares. The Houston oilfield-services firm reported Q1 revenue of $45.6 million, down from $50 million a year earlier, with a net loss of $0.4 million. U.S. revenue doubled while Canadian sales dropped sharply. No new company news drove the move.
RADX Shares Slip Ahead of Cancer-Imaging Update
Radiopharm Theranostics’ U.S.-listed shares last traded at $4.52, down 1.3% on volume of 325, as investors awaited new data from its lead cancer-imaging program. The company’s most recent update was a May 14 Zacks report, with topline Phase 2 trial results for RAD101 expected around the end of June. Radiopharm reported A$19.2 million in cash as of March 31.
PRCT rises as Wall Street slips; investors look again at Aquablation
PROCEPT BioRobotics shares rose 0.6% to $28.29 in early Thursday trading, outperforming broader medical device stocks as Wall Street opened lower. The move follows the American Urological Association’s strengthened recommendation for Aquablation therapy. PROCEPT reported Q1 revenue of $83.1 million, up 20%, but posted a wider net loss of $31.6 million. The company reaffirmed 2026 revenue guidance of $390–$410 million.
Entegris Stock Is Stuck While AI Chip Demand Booms — Here’s What Traders Are Testing
Entegris shares were little changed at $127.75 in early Nasdaq trading Thursday, underperforming chip-equipment peers. The company reported Q1 net sales of $812 million and guided Q2 sales of $815–$845 million. Sukhi Nagesh became CFO on May 18. Analysts remain split, with price targets ranging from $115 to $205.
Quantum Shares Tick Up in Pre-Market Trade After AI Storage Angle Draws Notice
Quantum Corp shares climbed 5.88% to $8.64 in pre-market trading Thursday after closing 5.84% higher Wednesday. No new company news accompanied the move. Quantum last reported fiscal Q3 revenue of $74.6 million and a GAAP net loss of $27.8 million. The company’s market value stands near $112 million, far below larger peers NetApp and Dell.
Bright Minds Biosciences Up After $220 Piper Sandler Call—Key Level for DRUG Traders
Bright Minds Biosciences shares jumped 11.1% to $82.78 after Piper Sandler raised its price target to $220 and reiterated an “Overweight” rating. The company reported C$309.7 million in cash at March 31, up from C$82.9 million in September, and a wider net loss. Lead drug BMB-101 completed Phase 1 and reported Phase 2 data for epilepsy and absence seizures.
Spark I gets Nasdaq notice ahead of Kneron deadline
Spark I Acquisition Corp disclosed it fell below Nasdaq’s minimum 400-holder requirement, triggering a compliance notice received May 14. Shares closed Wednesday at $12.40, about 8.9% above redemption value, with a $107.37 million market cap. The company has 45 days to submit a compliance plan and is negotiating a merger with Kneron Holding Corporation. Spark reported no revenue and a $94,195 net loss for Q1.
Bio-Techne Shares Bounce, Investors Eye a Key Risk
Bio-Techne closed Wednesday at $46.70, up 2.7%, marking a three-day rebound but still 35% below its January high. Fiscal third-quarter revenue fell 2% to $311.4 million, missing Wall Street estimates as weak biotech demand and U.S. academic funding cuts weighed on sales. CEO Kim Kelderman described the academic market as “frail” and not on a clear recovery path. Bio-Techne owns 20% of Wilson Wolf and may acquire the rest.
Aterian Moves Lower Pre-Market With $18 Million Ballot Ahead
Aterian shares fell 2.5% to $1.15 in premarket trading Thursday after a May 15 filing showed a wider first-quarter loss and raised “substantial doubt” about its ability to continue. The company is seeking stockholder approval to sell major brands for $18 million and issue $7 million in preferred stock, moves that could give investor David E. Lazar control of over 95% of the company.
Vanda Shares Move in Pre-Market Ahead of Nereus and Bysanti Data
Vanda Pharmaceuticals shares fell 0.5% to $6.15 in premarket trading Thursday, trimming part of Wednesday’s 3.2% gain. First-quarter net product sales rose 3% to $51.7 million, but the company posted a $48.6 million net loss and used $50.2 million in operating cash. Vanda raised 2026 revenue guidance to $240–$290 million, expecting Nereus to contribute up to $30 million this year.
EHGO Shares Approach 52-Week Lows as Eshallgo Pops Up on Nasdaq Radar Again
EHGO closed at $1.55 on Wednesday, down 4.32%, after hitting a 52-week low of $1.42. The Nasdaq-listed company recently regained compliance with minimum bid rules after a 16-for-1 reverse split. Shareholders approved raising Class B voting rights to 400 votes per share and authorized further share consolidations. Eshallgo’s market value stands near $3.14 million.
LIMN Stock Rises in Pre-Market on Liminatus InnocsAI Deal News
Liminatus Pharma agreed to acquire InnocsAI in an all-stock deal, issuing 1.6 billion shares at $0.20 each—over 35 times its current share count. LIMN rose 51% to $0.2844 in premarket trading. The deal would add CAR-T cancer therapy assets, including a candidate authorized for a Phase 1/2a study in South Korea. Liminatus reported $1.91 million in cash and warned of “substantial doubt” about its ability to continue.
Cintas Stock Just Lost Its Rebound — Why CTAS Traders Are Watching the UniFirst Deal
Cintas shares closed Wednesday at $171.36, down 0.49%, after giving back gains from a 3.68% jump Monday. The stock lagged the S&P 500, which rose 1.1% the same day. Investors are watching Cintas’ pending $5.5 billion UniFirst acquisition and projected $375 million in cost synergies. Cintas reported fiscal Q3 revenue of $2.84 billion, up 8.9%, and raised its full-year outlook.
Aimei Health: Nasdaq Sends AFJK 60-Day Notice
Aimei Health received a Nasdaq deficiency notice after missing the May 15 deadline for its March-quarter 10-Q filing. Shares traded at $42.18 in pre-market activity ahead of Thursday’s U.S. session. The company has 60 days from the May 19 notice to regain compliance or risk delisting. Aimei is also seeking to complete a merger with United Hydrogen Group, pending regulatory approval.
NMFC Stock Moves Higher Ahead of Open as New Mountain Finance Buyback Faces Private Credit Trial
New Mountain Finance Corp. closed Wednesday at $8.12, about 26% below its March 31 net asset value of $10.92 per share. The company reported Q1 adjusted net investment income of $32.2 million and declared a 25-cent quarterly distribution. NMFC cut statutory debt-to-equity to 1.12 times and completed a $470 million portfolio sale. Analysts’ average price target stands at $8.54, with most holding a neutral view.
Neurogene Trades Around $27 With Street Watching Rett Data Test Midyear
Neurogene Inc. shares closed at $26.95 Wednesday, up 0.3%, with little movement before Thursday’s Nasdaq open. About 90% of participants have been dosed in the registrational Embolden trial for NGN-401, with completion expected in Q2. Neurogene reported $243.2 million in cash as of March 31, enough to fund operations into early 2028. The company’s latest filings were posted May 12, with no new updates since.